Want to see SE:SUBGEN full AI Analyst Report?
SUBGEN Stock Chart & Stats
kr0.05
>-kr0.01(-10.34%)
―
--
Day’s Range― - ―
52-Week Rangekr0.04 - kr19.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)211.16K
Market Cap
kr103.43M
Enterprise Valuekr260.30M
Total Cash (Recent Filing)kr25.52M
Total Debt (Recent Filing)kr285.65M
Price to Earnings (P/E)―
Beta5.42
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding1,482,451,200
10 Day Avg. Volume272,161
30 Day Avg. Volume211,159
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00073
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery With Solid Gross MarginReturn of meaningful revenue in 2025 combined with an approximately 37% gross margin indicates the company can monetize its offerings and cover variable costs. Sustained mid-to-high gross margins support scalable unit economics as commercial activity ramps, improving long-term margin recovery prospects.
Moderate Leverage And Positive EquityA debt-to-equity near 0.24 and positive equity provide some financial flexibility versus highly leveraged peers. Moderate leverage reduces near-term solvency strain, lowers risk of immediate creditor pressure, and gives management more runway to execute commercial scaling without excessive refinancing urgency.
Focused IVD Diagnostics Business ModelA clear focus on in-vitro diagnostics concentrates R&D, regulatory, and commercial efforts in a durable healthcare niche. Specialization helps build domain expertise, regulatory know-how, and targeted go-to-market channels, supporting sustainable competitive positioning in diagnostics over the medium term.
Bears Say
Structural UnprofitabilityPersistent deep operating and EBITDA losses indicate fixed-cost intensity and a business not yet achieving operational leverage. Without sustained profit improvement, the company will remain reliant on financing, limiting strategic optionality and raising the risk that margins fail to normalize as revenue scales.
Consistent Negative Cash GenerationRepeat negative operating and free cash flow demonstrates ongoing cash burn despite revenue recovery. This structural cash deficit necessitates external funding, creating dilution or refinancing risk and constraining investments in commercialization, R&D, or margin-improving initiatives over the medium term.
Balance-sheet Volatility And Prior Negative EquityPrior periods of negative equity reflect past capital shortfalls and dilution events, indicating governance and funding stress. This history raises the probability of future equity raises under duress, which can dilute shareholders and constrain long-horizon planning for commercialization and R&D investments.
SUBGEN FAQ
What was AegirBio AB’s price range in the past 12 months?
AegirBio AB lowest stock price was kr0.04 and its highest was kr19.68 in the past 12 months.
What is AegirBio AB’s market cap?
AegirBio AB’s market cap is kr103.43M.
When is AegirBio AB’s upcoming earnings report date?
AegirBio AB’s upcoming earnings report date is Aug 20, 2026 which is in 24 days.
How were AegirBio AB’s earnings last quarter?
Currently, no data Available
Is AegirBio AB overvalued?
According to Wall Street analysts AegirBio AB’s price is currently Undervalued.
Does AegirBio AB pay dividends?
AegirBio AB does not currently pay dividends.
What is AegirBio AB’s EPS estimate?
AegirBio AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AegirBio AB have?
AegirBio AB has 1,482,451,200 shares outstanding.
What happened to AegirBio AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AegirBio AB?
Currently, no hedge funds are holding shares in SE:SUBGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AegirBio AB
Subgen AI AB develops artificial intelligence-based models and applications to control data for government and businesses. The company engages in the provision of information society services aimed at delivering financial and related knowledge tools to facilitate third-party access to financial literacy and instruments that enable them to interpret such information through e-learning; the acquisition, ownership, management and administration of securities; and the acquisition, ownership, marketing, leasing and operation of rural or urban properties. It also provides financial intermediation services; computer programming activities, structure and content design, writes computer code for systems, computer software, databases and web pages; and customizes computer programs, including configuration and modification of legacy programs. In addition, the company offers marketing and after-sales services of diagnostic imaging machinery and human resources services, as well as development of state-of-the-art artificial intelligence (Al) systems. Further, it provides Serenity Star, AI4D core, and Substrate Cloud. The company is based in London, United Kingdom. Subgen AI AB operates as a subsidiary of Substrate Artificial Inteligence, S.A.